These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18037543)

  • 41. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.
    Jones BG; Sealy RE; Rudraraju R; Traina-Dorge VL; Finneyfrock B; Cook A; Takimoto T; Portner A; Hurwitz JL
    Vaccine; 2012 Jan; 30(5):959-68. PubMed ID: 22119594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.
    Takimoto T; Hurwitz JL; Coleclough C; Prouser C; Krishnamurthy S; Zhan X; Boyd K; Scroggs RA; Brown B; Nagai Y; Portner A; Slobod KS
    J Virol; 2004 Jun; 78(11):6043-7. PubMed ID: 15141002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.
    Scaggs Huang F; Bernstein DI; Slobod KS; Portner A; Takimoto T; Russell CJ; Meagher M; Jones BG; Sealy RE; Coleclough C; Branum K; Dickey M; Buschle K; McNeal M; Makowski M; Nakamura A; Hurwitz JL
    Hum Vaccin Immunother; 2021 Feb; 17(2):554-559. PubMed ID: 32750273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.
    Takimoto T; Hurwitz JL; Zhan X; Krishnamurthy S; Prouser C; Brown B; Coleclough C; Boyd K; Scroggs RA; Portner A; Slobod KS
    Viral Immunol; 2005; 18(2):255-66. PubMed ID: 16035938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
    McGinnes Cullen L; Schmidt MR; Kenward SA; Woodland RT; Morrison TG
    J Virol; 2015 Jul; 89(13):6835-47. PubMed ID: 25903340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.
    Cullen LM; Blanco JC; Morrison TG
    J Transl Med; 2015 Nov; 13():350. PubMed ID: 26541285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
    O'Konek JJ; Makidon PE; Landers JJ; Cao Z; Malinczak CA; Pannu J; Sun J; Bitko V; Ciotti S; Hamouda T; Wojcinski ZW; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2015; 11(12):2904-12. PubMed ID: 26307915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
    Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
    J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Baculovirus expression of the respiratory syncytial virus fusion protein using Trichoplusia ni insect cells.
    Parrington M; Cockle S; Wyde P; Du RP; Snell E; Yan WY; Wang Q; Gisonni L; Sanhueza S; Ewasyshyn M; Klein M
    Virus Genes; 1997; 14(1):63-72. PubMed ID: 9208456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.
    Kohlmann R; Schwannecke S; Tippler B; Ternette N; Temchura VV; Tenbusch M; Uberla K; Grunwald T
    J Virol; 2009 Dec; 83(23):12601-10. PubMed ID: 19776123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.